Mechanism of action of the trastuzumab biosimilar CT-P6-Reference-Cited by-同舟云学术

Mechanism of action of the trastuzumab biosimilar CT-P6

Published:2018-12-13 Issue:10 Volume:19 Page:1085-1095
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Jeong Sun Ah¹,Choi Jung Min¹,Park Jun Mo¹,Lee Jun Young¹,Lee So Jung¹,Lee Su Yeon¹,Lee Si Yeon¹,Park Yoon A¹,Jeong Hee Jeong¹,Song Yoo Cheol¹,Kim Sung Hwan¹,Chang Shin Jae¹

Affiliation:

1. Biotechnology Research Institute, Celltrion Inc, Incheon, Republic of Korea

Funder

Celltrion Inc

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2019.1554052

Reference58 articles.

1. Her2-positive breast cancer: Herceptin and beyond

2. HER2-positive breast cancer

3. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

4. Trastuzumab — Mechanism of Action and Use in Clinical Practice

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging role of biosimilars: Focus on trastuzumab and metastatic human epidermal growth factor receptor 2-positive breast cancer;Results in Chemistry;2023-12

2. A phase 2 multicenter study of docetaxel‐PM and trastuzumab‐pkrb combination therapy in recurrent or metastatic salivary gland carcinomas;Cancer;2023-05-28

3. Evaluation of Biosimilar Trastuzumab MYL-1401O in HER2-Positive Breast Cancer;The American Journal of Managed Care;2022-09-14

4. Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer;Biomedicines;2022-08-21

5. Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data;The Breast;2022-04